Drug discovery articles from across Nature Portfolio

Despite mixed efficacy outcomes, a phase 1/2 umbrella trial brings the glioblastoma field closer to a new era of diagnostic precision and targeted therapy.

A deep-learning algorithm unravels a collection of archaeasins, peptides from the archaeal proteome with potential antimicrobial activity and implications for the development of next-generation antibiotics

Most bacteria cannot be grown in the laboratory, which means that their genetic diversity is hidden to traditional culture-based studies. We combined a new DNA extraction method, long-read sequencing, bioinformatics and chemical synthesis to access the genetic diversity of uncultured soil bacteria and abiotically decode it to discover bioactive small molecules.

A novel state-of-the-art approach for absolute binding free energies of RNA-binding small molecules paves the way to the routine use of free-energy simulations in drug discovery targeting RNA systems, reducing failure rates.

Experiments show that the bacterial component of fine particulate matter has a highly potent inflammatory effect.

Inhibitors of ferroptosis are key tools for studies of cell death and may ultimately prove useful for the treatment of various diseases. In this Comment, we discuss major types of ferroptosis inhibitors and considerations for their use in mechanistic and preclinical studies.

Despite mixed efficacy outcomes, a phase 1/2 umbrella trial brings the glioblastoma field closer to a new era of diagnostic precision and targeted therapy.

The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of medicines has emerged as transformative for the treatment of diabetes, obesity and other diseases. On the twentieth anniversary of the approval of exenatide (Byetta), three former employees of Amylin Pharmaceuticals acknowledge the contributions of some of the individuals and the innovation responsible for delivering the first approved GLP-1RA — the forerunner to the modern blockbuster drugs.

A deep-learning algorithm unravels a collection of archaeasins, peptides from the archaeal proteome with potential antimicrobial activity and implications for the development of next-generation antibiotics

Most bacteria cannot be grown in the laboratory, which means that their genetic diversity is hidden to traditional culture-based studies. We combined a new DNA extraction method, long-read sequencing, bioinformatics and chemical synthesis to access the genetic diversity of uncultured soil bacteria and abiotically decode it to discover bioactive small molecules.